Similar trends were observed with nivolumab plus ipilimumab versus chemotherapy in the tumor PD-L1 < 1% population (n = 54); median (95% CI) OS was 41.5 (19.4–62.6) versus 18.2 (7.4–30.3) months (HR 0.55; 95% CI, 0.29–1.04) and the 5-year OS (95% CI) rate was 36% (18%–54%) versus 19% (7%–35%) (Fig. 1B). This evidence concerns the gene CD274 and neoplasm.